ArticleHaematologica2023
TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma.
Max J Gordon, David A Bond, Adam S Kittai, Neda Amirmokhtari, Abigail Steinbrunner, Allison Huffman, Victor Orellana-Noia, Geoffrey Shouse, Jonathon B Cohen, Tycel Phillips and 1 more
Open access · goldAbstract readLetter
In one paragraphArticle in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors at 5 institutions in 1 country.
Max J GordonUniversity of Texas M.D. Anderson Cancer Center, Houston, TX. mjgordon@mdanderson.org.
David A BondOhio State University, James Cancer Center, Columbus, OH.
Adam S KittaiOhio State University, James Cancer Center, Columbus, OH.
Neda AmirmokhtariOhio State University, James Cancer Center, Columbus, OH.
Abigail SteinbrunnerOhio State University, James Cancer Center, Columbus, OH.
Allison HuffmanOhio State University, James Cancer Center, Columbus, OH.
Victor Orellana-NoiaEmory University Winship Cancer Institute, Atlanta, GA.
Geoffrey ShouseCity of Hope National Medical Center, Duarte, CA.
Jonathon B CohenEmory University Winship Cancer Institute, Atlanta, GA.
Tycel PhillipsCity of Hope National Medical Center, Duarte, CA.
Alexey V DanilovCity of Hope National Medical Center, Duarte, CA. adanilov@coh.org.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USCity Of Hope National Medical Center · USEmory University · USThe University of Texas MD Anderson Cancer Center · USWinship Cancer Institute
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3MTRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8MOvercoming ibrutinib resistance in mantle cell lymphomaR01CA244576 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI DANILOV, ALEXEY V. · 2021 to 2025
$2.2MNCI NIH HHS P30 CA016058NCI NIH HHS R01 CA244576NCI NIH HHS T32 CA009666
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Lymphoma, Mantle-CellAdultAgedComorbidityHumans
Identifiers
PMID37226703
PMCPMC10620592
OpenAlexW4378172938
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390